Budesonide in Patients With Immune Mediated Enteropathies
Status:
Terminated
Trial end date:
2021-10-19
Target enrollment:
Participant gender:
Summary
Researchers are trying to determine if withdrawal of budesonide therapy in patients with
immune-mediated enteropathies doing well on therapy will result in worsening symptoms,
histology, quality of life, and micronutrient/nutritional status when compared to continued
therapy.